

5 June 2009

Proposal to list a new brand of tamoxifen (Tamoxifen Sandoz)

PHARMAC is seeking feedback on a proposal to list an additional brand of tamoxifen citrate (Tamoxifen Sandoz) in the Pharmaceutical Schedule.

Details of the proposal

PHARMAC and Sandoz Pty Limited have entered into a provisional agreement for the listing of its brand of tamoxifen citrate (Tamoxifen Sandoz) in the Pharmaceutical Schedule. We are now seeking feedback on this proposal. Details of the proposal are as follows:

Tamoxifen Sandoz would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 August 2009 at the following prices and subsidies (ex-manufacturer, exclusive of GST):

Chemical	Presentation	Brand	Pack size	Proposed price and subsidy
Tamoxifen citrate	Tab 20 mg	Tamoxifen Sandoz	60	\$6.66

Tamoxifen Sandoz would be protected from delisting and subsidy reduction until 1 July 2011.

We are not proposing to make any changes to the listing or subsidies for the Mylan brand of tamoxifen.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback please submit it in writing by 4 pm on **Friday, 19 June 2009** to:

Jackie Evans
 Therapeutic Group Manager
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email: jackie.evans@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.